BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1473 related articles for article (PubMed ID: 29056243)

  • 1. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
    Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
    Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic value of tumoral heterogeneity and volumetric parameters as measured by F18-FDG PET/CT in sinonasal cancer.
    Kim BS; Pak K; Yi KI; Kim IJ; Roh HJ; Cho KS
    Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1437-1443. PubMed ID: 27747383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic evaluation of the prognostic value of
    Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
    Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
    Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
    Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
    Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomograms based on SUVmax of
    Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
    Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
    Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
    Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 12. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from
    Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1787-1795. PubMed ID: 28616695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Texture analysis of
    Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
    Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
    Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pretreatment evaluation of
    Peng P; Wu N; Tao XL; Liu Y; Lyu L; Cheng X
    Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):370-376. PubMed ID: 35448927
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
    Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
    Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
    Chang S; Kim SJ
    Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
    Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
    PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.